Similar articles

• An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.

  McDonald H, Hux M, Brisson M, Bernard L, Nickel JC. McDonald H, et al. Can J Urol. 2004 Aug;11(4):2327-40. Can J Urol. 2004. PMID: 15380054
• [Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].

  Lopatkin NA, Ziborova IV, Sivkov AV, Apolikhin OI. Lopatkin NA, et al. Urol Nefrol (Mosk). 1999 Jan-Feb;(1):22-6. Urol Nefrol (Mosk). 1999. PMID: 11149340 Russian.
• The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

  McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. McConnell JD, et al. N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656. N Engl J Med. 2003. PMID: 14681504 Clinical Trial.
• [Benign prostatic hyperplasia: medical therapy].

  Schlenker B, Gratzke C, Weidlich P, Seitz M, Reich O, Stief CG. Schlenker B, et al. MMW Fortschr Med. 2007 Aug 16;149(33-34):29-31; quiz 32. MMW Fortschr Med. 2007. PMID: 17912863 Review. German.
• Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.

  Bhardwa J, Goldstraw M, Tzortzis S, Kirby R. Bhardwa J, et al. Expert Opin Pharmacother. 2007 Jun;8(9):1337-44. doi: 10.1517/14656566.8.9.1337. Expert Opin Pharmacother. 2007. PMID: 17563267 Review.